全文获取类型
收费全文 | 406903篇 |
免费 | 26722篇 |
国内免费 | 4905篇 |
专业分类
耳鼻咽喉 | 5379篇 |
儿科学 | 8578篇 |
妇产科学 | 10382篇 |
基础医学 | 56226篇 |
口腔科学 | 12257篇 |
临床医学 | 33853篇 |
内科学 | 82461篇 |
皮肤病学 | 8778篇 |
神经病学 | 28509篇 |
特种医学 | 15140篇 |
外国民族医学 | 94篇 |
外科学 | 63711篇 |
综合类 | 14645篇 |
现状与发展 | 7篇 |
一般理论 | 67篇 |
预防医学 | 19261篇 |
眼科学 | 10097篇 |
药学 | 33955篇 |
28篇 | |
中国医学 | 3758篇 |
肿瘤学 | 31344篇 |
出版年
2021年 | 3943篇 |
2020年 | 2651篇 |
2019年 | 3635篇 |
2018年 | 5434篇 |
2017年 | 4319篇 |
2016年 | 4400篇 |
2015年 | 5282篇 |
2014年 | 7225篇 |
2013年 | 8781篇 |
2012年 | 11878篇 |
2011年 | 12427篇 |
2010年 | 7619篇 |
2009年 | 6955篇 |
2008年 | 10868篇 |
2007年 | 11775篇 |
2006年 | 11655篇 |
2005年 | 10690篇 |
2004年 | 9856篇 |
2003年 | 9623篇 |
2002年 | 9172篇 |
2001年 | 28999篇 |
2000年 | 29460篇 |
1999年 | 24316篇 |
1998年 | 5560篇 |
1997年 | 4725篇 |
1996年 | 4154篇 |
1995年 | 3766篇 |
1994年 | 3325篇 |
1993年 | 3021篇 |
1992年 | 16227篇 |
1991年 | 14989篇 |
1990年 | 14295篇 |
1989年 | 14087篇 |
1988年 | 12679篇 |
1987年 | 12165篇 |
1986年 | 11183篇 |
1985年 | 10373篇 |
1984年 | 6943篇 |
1983年 | 5617篇 |
1982年 | 2726篇 |
1979年 | 5514篇 |
1978年 | 3369篇 |
1977年 | 2978篇 |
1975年 | 2653篇 |
1974年 | 3078篇 |
1973年 | 2875篇 |
1972年 | 2835篇 |
1971年 | 2775篇 |
1970年 | 2512篇 |
1969年 | 2547篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
T.-Y. Huang Y.-J. Hsia M.-Y. Sung Y.-T. Wu P.-C. Hsu 《International journal of oral and maxillofacial surgery》2021,50(8):1100-1106
Zygomatic implant treatment is widely applied for severe maxillary atrophy to help rehabilitate the maxillary dentition. This retrospective study was performed to evaluate the actual radiographic bone–implant contact (rBIC) lengths of zygomatic implants. The records of 28 patients who underwent zygomatic implant surgery and subsequent follow-up examinations between August 2013 and September 2018 in the Department of Oral and Maxillofacial Surgery, Taipei Tzu Chi Hospital were reviewed. The surgeries were performed by a single surgeon using the same treatment protocol. All patients had a computed tomography scan at 1 year after the surgery. Using three-dimensional imaging software, an investigator measured the rBIC lengths of 66 implants and documented their clinical status. The implant survival rate was 100%. The mean rBIC length was significantly longer in male patients than in female patients (20.80 ± 5.88 mm versus 17.79 ± 6.34 mm; P = 0.028). The mean rBIC length of double zygomatic implants was significantly longer when compared to that of single implants (21.11 ± 6.23 mm versus 17.75 ± 5.85 mm; P = 0.027). This article is novel in reporting the exact rBIC lengths of zygomatic implants in a clinical setting. The results showed that zygomatic implants are a viable treatment modality for full-mouth rehabilitation. 相似文献
22.
23.
Y. Ermias I.A. Morgan K.M. Curtis M.K. Whiteman L.G. Horton L.B. Zapata 《Contraception》2019,99(5):300-305
ObjectiveIdentify factors associated with healthcare providers' frequency of depot medroxyprogesterone acetate (DMPA) provision to adolescents.Study designWe analyzed data from surveys mailed to a nationally representative sample of public-sector providers and office-based physicians (n=1984). We estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) of factors associated with frequent DMPA provision to adolescents in the past year.ResultsAlthough most providers (>95%) considered DMPA safe for adolescents, fewer reported frequent provision (89% of public-sector providers; 64% of office-based physicians). Among public-sector providers, factors associated with lower odds of frequent provision included working in settings without Title X funding (aOR 0.44, 95% CI 0.30–0.64), reporting primary care as their primary clinical focus versus reproductive or adolescent health (aOR 0.42, 95% CI 0.28–0.61), and providing fewer patients with family planning services. Among office-based physicians, factors associated with lower odds of frequent provision included specializing in obstetrics/gynecology (aOR 0.50, 95% CI 0.27–0.91) and family medicine (aOR 0.21, 95% CI 0.09–0.47) versus adolescent medicine, completing training ≥15 versus <5 years ago (aOR 0.27, 95% CI 0.09–0.83), and reporting that 0–24% of patients pay with Medicaid or other government healthcare assistance versus ≥50% (aOR 0.23, 95% CI 0.09–0.61). The reason most commonly reported by providers for infrequent DMPA provision was patient preference for another method.ConclusionsWhile most providers reported frequently providing DMPA to adolescents, training on evidence-based recommendations for contraception, focused on subgroups of providers with lower odds of frequent DMPA provision, may increase adolescents' access to contraception.ImplicationsAlthough >95% of providers considered depot medroxyprogesterone (DMPA) a safe contraceptive for adolescents, only 89% of public-sector providers and 64% of office-based physicians reported frequently providing DMPA to adolescents. Provider training on evidence-based recommendations for contraception counseling and provision may increase adolescents' access to DMPA and all methods of contraception. 相似文献
24.
Prevention Science - This study aimed to evaluate the effectiveness of the drug and violence resistance educational program (PROERD) on short-term secondary outcomes, such as intentions to use... 相似文献
25.
26.
27.
Parallel enzyme‐linked immunosorbent assay screening for human immunodeficiency virus among blood donors in five Chinese blood centres: a retrospective analysis
下载免费PDF全文
![点击此处可从《Transfusion medicine (Oxford, England)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
28.
29.
Xue Yao Yan Zhang Jian Hao Hui-Quan Duan Chen-Xi Zhao Chao Sun Bo Li Bao-You Fan Xu Wang Wen-Xiang Li Xuan-Hao Fu Yong Hu Chang Liu Xiao-Hong Kong Shi-Qing Feng 《中国神经再生研究》2019,(3)
Ferroptosis is an iron-dependent novel cell death pathway. Deferoxamine, a ferroptosis inhibitor, has been reported to promote spinal cord injury repair. It has yet to be clarified whether ferroptosis inhibition represents the mechanism of action of Deferoxamine on spinal cord injury recovery. A rat model of Deferoxamine at thoracic 10 segment was established using a modified Allen's method. Ninety 8-week-old female Wistar rats were used. Rats in the Deferoxamine group were intraperitoneally injected with 100 mg/kg Deferoxamine 30 minutes before injury. Simultaneously, the Sham and Deferoxamine groups served as controls. Drug administration was conducted for 7 consecutive days. The results were as follows:(1) Electron microscopy revealed shrunken mitochondria in the spinal cord injury group.(2) The Basso, Beattie and Bresnahan locomotor rating score showed that recovery of the hindlimb was remarkably better in the Deferoxamine group than in the spinal cord injury group.(3) The iron concentration was lower in the Deferoxamine group than in the spinal cord injury group after injury.(4) Western blot assay revealed that, compared with the spinal cord injury group, GPX4, xCT, and glutathione expression was markedly increased in the Deferoxamine group.(5) Real-time polymerase chain reaction revealed that, compared with the Deferoxamine group, mRNA levels of ferroptosis-related genes Acyl-CoA synthetase family member 2(ACSF2) and iron-responsive element-binding protein 2(IREB2) were up-regulated in the Deferoxamine group.(6) Deferoxamine increased survival of neurons and inhibited gliosis. These findings confirm that Deferoxamine can repair spinal cord injury by inhibiting ferroptosis. Targeting ferroptosis is therefore a promising therapeutic approach for spinal cord injury. 相似文献
30.
HIV-1 infection usually leads to systemic chronic inflammation that is associated with gut microbial translocation. The recently defined group 3 innate lymphoid cells (ILC3s) are critical for maintenance of intestinal barrier function; however, it is not clear whether and how HIV-1 infection influences the function of these cells. In this issue of the JCI, Zhang and colleagues present compelling evidence that the survival and function of ILC3s are dramatically impaired by HIV-1 infection. The authors provide evidence that HIV-1 infection induces persistent activation of plasmacytoid dendritic cells (pDCs) and production of type I IFNs, which together increase expression of death receptor CD95 on ILC3s and thereby promote subsequent ILC3 apoptosis. Together, these results identify a mechanism that explains the impaired intestinal barrier function that results from chronic HIV-1 infection and shed light on the role of pDCs in HIV-1 immunopathogenesis and therapy. 相似文献